Daniel E Jonas

发表

Levels of Integration Matrix (Developed from the Integration Matrix Outlined in figure 3 of the 2008 AHRQ Review)

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

[Table], Quality Review for observational trials (Originally in EXCEL)

Daniel E Jonas, Meera Viswanathan, Kathleen N Lohr, 2009 .

Table 20, Advantages and disadvantages of the Bayesian MTC approach

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

Table 18, Simulation results: Probability of best treatment under superior efficacy scenario

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

[Table], Upper Tier Evidence Gaps (those receiving 5 or more stars)

Daniel E Jonas, Meera Viswanathan, Alan R. Ellis, 2012 .

[Table, Ongoing Trials Presented to Stakeholders for the First Conference Call].

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

[Table, AHRQ’s EHC Program Selection Criteria for New Research].

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

[Table], Level of integrated process of care

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Rationale for Final Prioritized List of Potential Research Studies (Detailing Rationale, PICOTS, and Study Design Considerations)

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Figure 11-1, Generic analytic framework for evaluating predictive genetic tests

Daniel E Jonas, David B. Matchar, Tania M Wilkins, 2012 .

Table 36, Summary of studies reporting on outcomes by primary clinical context and subtopic

Daniel E Jonas, Meera Viswanathan, Kathleen N Lohr, 2009 .

Table 43, Strength of evidence for the current and projected capacity to deliver CRC screening

Daniel E Jonas, Meera Viswanathan, Kathleen N Lohr, 2010 .

Flowchart of Future Research Needs (FRN) Process

Timothy S. Carey, Daniel E Jonas, Meera Viswanathan, 2012 .

Figure 11-2, Generic analytic framework for evaluating predictive genetic tests when the impact on family members is important

Daniel E Jonas, David B. Matchar, Tania M Wilkins, 2012 .

[Table, Power Analysis].

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Figure 12, One closed loop network pattern used in simulation

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

Table 7, Comparison of findings for mean change in HAM-D between Bayesian MTC meta-analysis findings and those of frequentist methods for various network patterns

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

Additional Relevant Characteristics and Study Design Considerations

Timothy S. Carey, Daniel E Jonas, Alan R. Ellis, 2012 .

Table A, Summary of findings, limitations, and recommendations from the 2008 AHRQ review (modified using table 19 of the original report)

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Timothy S. Carey, Daniel E Jonas, Meera Viswanathan, 2012 .

Table 11-2, ACCE model questions for reviews of genetic tests

Daniel E Jonas, Timothy J Wilt, David B. Matchar, 2012 .

Online Prioritization Exercises

Timothy S. Carey, Daniel E Jonas, Meera Viswanathan, 2012 .

Table 11-3, Questions for assessing preanalytic, analytic, and postanalytic factors for evaluating predictive genetic tests*

Daniel E Jonas, Timothy J Wilt, David B. Matchar, 2012 .

Table G-1, Additional relevant characteristics and study design considerations

Timothy S. Carey, Daniel E Jonas, Alan R. Ellis, 2012 .

Table 11-1, Principles for addressing common challenges when evaluating genetic tests used as predictive indicators

Daniel E Jonas, Timothy J Wilt, David B. Matchar, 2012 .

[Table], Abstract Review Form (Originally in Excel)

Daniel E Jonas, Meera Viswanathan, Kathleen N Lohr, 2009 .

[Table], Full-text review form (Originally in EXCEL)

Daniel E Jonas, Meera Viswanathan, Kathleen N Lohr, 2009 .

[Table], Abstraction Form for Evidence Tables (Originally in EXCEL)

Daniel E Jonas, Meera Viswanathan, Kathleen N Lohr, 2009 .

Analytic Framework (figure 1 from the 2008 AHRQ review)

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Table 8, Comparison of findings for ACR 50 response between Bayesian MTC meta-analysis findings and those of frequentist methods for various network patterns

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

Interim Results from the First and Second Rounds of Prioritization with Stakeholders

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Web-Based Prioritization Exercises

Daniel E Jonas, Meera Viswanathan, Alan R. Ellis, 2012 .

Table H-2, Results from the Second Prioritization Exercise

Timothy S. Carey, Karen Crotty, Joseph P. Morrissey, 2010 .

Additional Tables and Study Results

Cynthia Feltner, Ina Wallace, Nancy D Berkman, 2018 .

IdentifyingPrioritiesfor Patient-CenteredOutcomes ResearchforSeriousMentalIllness

Daniel E Jonas, Meera Viswanathan, Pam Curtis, 2012 .

Table 1, Studies Attempting to Externally Validate Risk Stratification Tools to Distinguish Persons Who Are More or Less Likely to Have CAS

Daniel E Jonas, Halle R Amick, Russell Harris, 2014 .

Figure 4, Simulation study design

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

Quality Assessment Tables

Jennifer Cook Middleton, Daniel E Jonas, Mahima Ashok, 2016 .

Table 1, Preliminary evidence gaps by Key Question

Daniel E Jonas, Meera Viswanathan, Alan R. Ellis, 2012 .

Table 21, Possible targets for future research, by Key Question (KQ)

Daniel E Jonas, Gerald Gartlehner, Shrikant I. Bangdiwala, 2013 .

Methods for the Drug Effectiveness Review Project

Daniel E Jonas, Gerald Gartlehner, Mark Helfand, 2012, BMC Medical Research Methodology.

Drug Class Review: Constipation Drugs

Daniel E Jonas, Gerald Gartlehner, Laura C Morgan, 2007 .

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis

Daniel E Jonas, Michael Pignone, Kristen Hassmiller Lich, 2018, Circulation. Cardiovascular quality and outcomes.

Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis.

Daniel E Jonas, Meera Viswanathan, Gerald Gartlehner, 2014, The Journal of clinical psychiatry.

Genetic and clinical factors relating to warfarin dosing.

Daniel E Jonas, Howard L McLeod, H. McLeod, 2009, Trends in pharmacological sciences.